Phase 1 N=15 Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects
Intra-subject Variability of Pharmacokinetics
Primary: Cmax — 0.961; 2.34; 23.6; 1.02 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Anti-Psychotic · Management of Manifestations of Psychotic Disorders · Treatment of Schizophrenia
Primary: Maximum Observed Plasma Concentration (Cmax) - Chlorpromazine — 2671; 2720 pg/mL
Phase 1 N=24 Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution
Asthma
Primary: Area Under the Plasma Concentration-time Profile From Time 0 the Last Quantifiable Concentration (AUC0-last) With Dose Normalization — 658; 700; 716; 748 pg.h/mL…
Phase 3 N=13 A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
Pulmonary Arterial Hypertension
Primary: To Assess the Pharmacokinetics (Mean AM Dose) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen…
N/A N=64 Effect of Inflammation on Pharmacokinetics of Posaconazole
Mycoses
Primary: C Reactive Protein Levels in mg/L (CRP) on Posaconazole Concentrations in mg/L — 1.8; 23.5 mg/L — p=0.77
Phase 4 N=43 Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
Hepatic Failure · Hepatic Impairment · Chronic Hepatitis C Infection With Hepatic Coma
Primary: Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC0-last) of Buprenorphine, Norbuprenorphine, Naloxone and…
Phase 1 N=40 Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab
Plasma Concentrations
Primary: Cmax — 34.96; 249.55 pg/mL
Phase 4 N=105 Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery
Pain · Other Surgical Procedures · Impacted Third Molar Tooth
Primary: Score of Pain Measured by Visual Analogue Scale — 25 score on a scale (mm)
Phase 1 N=30 Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
Epilepsy
Primary: Maximum Drug Concentration (Cmax) — 9469; 9867; 15067; 17309 ng/mL
Phase 4 N=12 Pharmacokinetics (PK) of Ertapenem Intravenous (IV) Bolus Versus Standard Infusion
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) at Steady-State (After 3rd Dose) — 193.33; 165.70 mcg/mL
Phase 1 N=14 A Single-Dose Trial to Examine the Within Subject Variability of Clexane® in Healthy Adults Under Fasting Conditions
Clexane is Administered to Healthy Volunteers
Primary: Anti-FXa Cmax — 0.999; 0.926 IU/mL
Phase 1 N=28 Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone
Parkinson Disease
Primary: Cmax - Maximum Observed Plasma Concentration — 327.8; 750.1 ng/mL
Phase 1 N=16 Eletriptan Pharmacokinetics In Korean Males
Healthy
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] — 291.3; 575.6; 1282.0; 1278.0 ng* hr/mL
Phase 1 N=105 Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects
Parkinson Disease
Primary: Cmax of BIA 9-1067 - Maximum Observed Plasma Concentration of BIA 9-1067 (Day 1) — 182; 794; 1540; 176 ng/mL
Phase 1 N=17 An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
Epilepsy
Primary: Area Under the Plasma Concentration Versus Time Curve, AUC(0-tlast). — 954.891; 49.750; 240188.369; 234750.429 h·ng/mL
Phase 2 N=143 Evaluate Safety, Efficacy and Pharmacokinetics
Metastatic Breast Cancer
Primary: Area Under the Concentration Time Curve at Steady State (AUCss) — 34400; 31800 ug*h/mL
N/A N=21 Pharmacokinetics of Ketamine in Infants and Children
The Pk of IV Ketamine in Children With Heart Disease
Primary: Total Clearance and Intercompartmental Clearance — 60.0; 70.8 L/h/70kg
Phase 1 N=24 Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects
Parkinson Disease
Primary: Cmax - Maximum Plasma Concentration — 407.4; 391.1; 439.6; 382.0 ng/mL
Phase 4 N=60 Pharmacokinetics of Preoperative Vancomycin
Surgical Site Infection · Vancomycin
Primary: Pharmacokinetics Analysis: V˅c — 2.56; 1.14 L
Phase 4 N=34 Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns
Depression
Primary: Comparision of the Buproprion Area Under the Concentration Time Curve (AUC) From Time 0 to 96 Hours by Type of Formulation and Dosage — 469; 667; 706; 1002…
N/A N=106 Variability in Adrenergic Response
Vascular Reaction to Medications
Primary: ED50 After Phenylephrine — 172; 310 ng/min
Phase 1 N=24 Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment
Hepatic Impairment
Primary: Maximum Plasma Concentration (Cmax) of PF-05221304 — 1220; 1591; 1433; 1592 Nanogram per milliliter (ng/mL)
Phase 4 N=4 BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients
Epilepsy
Primary: AUC — 79640; 81653 ng*hr/ml
Phase 1 N=13 The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin
Epilepsy
Primary: Cmax - Maximum Steady-state Plasma Concentration — 31652 ng/mL
Phase 4 N=95 Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics
Pain · Fever · Hepatotoxicity
Primary: Acetaminophen Plasma Clearance Association With Race/Ethnicity — 5.3; 5.9 mL/min/kg — p=0.52
Phase 1 N=18 Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093
Epilepsy
Primary: Cmax - the Maximum Plasma Concentration — 18048; 16007; 17042 ng/mL
Phase 3 N=38 Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases
Primary Immune Deficiency Disorders · Common Variable Immunodeficiency · X-linked Agammaglobulinaemia
Primary: Data (Derived From Absolute Concentration) Were Pooled With Historical Data and a Treatment Variable Defined (Subgam-VF or Gammaplex 5% IGIV). Outcome Measure Defined as…
N/A N=18 Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P
Pharmacokinetics
Primary: Plasma Nicotine Concentration-time Profile — 0.751; 0.336; 0.205; 0.478 ng/mL
Phase 1 N=40 An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
Epilepsy
Primary: Cmax - Peak Plasma Concentration — 14286.790; 18677.265; 15055.632; 14974.79 ng/mL
N/A N=30 Correlation of Mesalamine Pharmacokinetics With Local Availability
Local Drug Concentration in Gastrointestinal Tract
Primary: The AUC of Mesalamine in Plasma — 40.8; 57.6; 36.8; 7.9 nM*h